Perspective
ADHD Drugs and Cardiovascular Risk
N Engl J Med 2006; 354:1445-1448April 6, 2006
- Article
On February 9, 2006, the Drug Safety and Risk Management Advisory Committee of the Food and Drug Administration (FDA) voted by a narrow margin — eight to seven — to recommend a “black-box” warning describing the cardiovascular risks of stimulant drugs used to treat attention deficit–hyperactivity disorder (ADHD). This action was unexpected, largely because the FDA had not requested a review of current labeling for this class of drugs; it had merely asked for recommendations of approaches to studying the cardiovascular risks associated with these drugs. The committee, however, decided to take an independent course. As a consultant to this committee, I introduced two motions, one recommending the black-box warning and the other proposing the development of a guide for patients, which was approved by a vote of 15 to 0. The guides are handouts that are required to be provided at the time prescriptions are dispensed; they contain information, written in nontechnical language, about the potential hazards of the medication.
The drugs under review were primarily amphetamines (Adderall and other brands) and methylphenidate (Ritalin, Concerta, and other brands). These agents are closely related members of the class of sympathomimetic amines, the structures of several of which are shown in the diagram
Molecular Structures of Sympathomimetic Amines.. These compounds exert potent stimulant effects on the cardiovascular and central nervous systems. One of the oldest such agents, methamphetamine, was originally synthesized in 1891 and first widely used during World War II in Nazi Germany to enhance the ability of Luftwaffe pilots to stay alert during extended hours of combat. Medical use of this agent is now limited, but illicit use has grown rapidly and now represents an increasing public health problem. When smoked or injected intravenously, methamphetamine (“speed”) is associated with hyperthermia, rhabdomyolysis, myocardial infarction, stroke, and sudden death — effects well known to coroners in regions of the United States where abuse is common. Beginning in the 1950s, the stereoisomer dextroamphetamine and related agents were introduced as appetite suppressants.ADHD is a disorder commonly diagnosed in school-age boys (less commonly in girls) and is characterized by increased activity, an inability to concentrate, and poor school performance. The effectiveness of stimulants in treating ADHD has been well documented in randomized clinical trials. Amphetamines and amphetamine-like stimulants were introduced to treat ADHD in the 1950s, but the frequency of this diagnosis and the use of stimulants to treat it have accelerated enormously in recent years. The FDA advisory committee heard testimony indicating that 2.5 million children now take stimulants for ADHD, including nearly 10 percent of all 10-year-old boys in the United States.1 The committee also learned that the use of these agents is much less prevalent in European countries, where the diagnosis of ADHD is relatively uncommon. Even more strikingly, 1.5 million adults now take such stimulants on a daily basis, with 10 percent of users older than 50 years of age. The diagnosis of “adult” ADHD is a relatively recent phenomenon and has resulted in the most rapid growth in the use of such agents.1
The concern of the advisory committee reflected several considerations. The cardiovascular effects of the sympathomimetic amines have been thoroughly described in the medical literature. These agents substantially increase the heart rate and blood pressure. In a placebo-controlled trial, mixed amphetamine salts (Adderall) administered to adults increased systolic blood pressure by about 5 mm Hg; similar effects were found with methylphenidate formulations.2 Blood-pressure changes of this magnitude, particularly during long-term therapy, are known to increase morbidity and mortality. In 2005, a separate FDA advisory committee that I chaired concluded that blood-pressure changes represented such a reliable predictor of cardiovascular outcomes that class labeling would be appropriate in most cases.3 The increases in heart rate induced by sympathomimetic agents also have well-described adverse cardiovascular effects. The administration of these drugs produces persistent increases in heart rate, inducing chronic heart failure in animal models of dilated cardiomyopathy.
A review of the regulatory history of this class of drugs also helps to explain why the advisory committee took decisive action. The dietary supplement ephedra, sometimes called ma huang, contains two alkaloids, ephedrine (see diagram) and its enantiomer, pseudoephedrine. These supplements have been used by millions of Americans to assist in weight loss or to increase energy. Some athletes have advocated the use of ephedra-containing dietary supplements as performance-enhancing agents. On December 31, 2003, federal officials announced plans to ban ephedra immediately. Health and Human Services Secretary Tommy Thompson told reporters, “The time to stop using these products is now.” This action followed several high-profile catastrophic outcomes linked to ephedra products, including the death of 23-year-old Baltimore Orioles pitcher Steve Bechler. Published studies reported that sales of ephedra-containing supplements represented less than 1 percent of all dietary-supplement sales but that these products accounted for 64 percent of the serious adverse reactions to supplements reported to the Centers for Disease Control and Prevention.4 Unfortunately, in April 2005, a federal court in Utah struck down the federal ban on ephedra. Many companies that make these products are located in Utah.
Similar regulatory actions have been proposed for phenylpropanolamine (PPA), another closely related sympathomimetic amine (see diagram). On December 22, 2005, the FDA issued a notice of “proposed rulemaking for over-the-counter nasal decongestant and weight control products” containing PPA. The notice called for a public comment period until March 22, 2006, after which the FDA would undertake regulatory action that would probably include banning the use of the agent in over-the-counter preparations. The FDA's action followed many years of concern about the potential of PPA products to cause hemorrhagic stroke. Six years ago, a case–control study published in the Journal reported a 16-fold increase in the risk of stroke among women taking PPA for appetite suppression.5
Briefing documents prepared for the February 9 advisory-committee meeting described cases of myocardial infarction, stroke, and sudden death in children and adults taking ADHD stimulants.1 These narratives were derived from the FDA's Adverse Event Reporting System (AERS), a database containing reports of adverse events submitted by health care providers. The AERS is a voluntary reporting system that has been criticized because only 1 to 10 percent of serious adverse events are actually reported, limiting the database's usefulness for identifying emerging drug hazards. The drug-related events reviewed by the committee included 25 cases of sudden death in children or adults (see table
Cases of Sudden Death Reported to the FDA Advisory Committee from the AERS Database.), some with evidence on autopsy of undiagnosed congenital heart disease, such as hypertrophic obstructive cardiomyopathy. The physiology of this condition renders patients particularly vulnerable to the adverse effects of sympathomimetic drugs, because such agents increase contractility, thereby increasing the pressure gradient in the left ventricular outflow tract. Many additional cases of major adverse cardiovascular events, including myocardial infarction, stroke, and serious arrhythmias, were reviewed by the committee. However, the documentation of cases was frequently incomplete, and neither the FDA reviewers nor the committee considered the AERS data to be definitive.Despite the difficulty of interpreting these data, the advisory committee acted preemptively to recommend strong regulatory action. The majority of the group accepted my argument that the propensity of sympathomimetic agents to raise blood pressure and heart rate, the history of serious adverse effects associated with two members of the class (ephedra and PPA), and the rapid increase in exposure, particularly among adults, warranted strong and immediate action. Although the committee recognized that there are important potential benefits of these drugs for certain highly dysfunctional children, we rejected the notion that the administration of potent sympathomimetic agents to millions of Americans is appropriate. We sought to emphasize more selective and restricted use, while increasing awareness of potential hazards. We argued that the FDA should act soon, and decisively.
This article was published at www.nejm.org on March 20, 2006.
An interview with Dr. Nissen can be heard at www.nejm.org.
Source Information
Dr. Nissen is the interim chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic, Cleveland, and was a consultant to the FDA's Drug Safety and Risk Management Advisory Committee for the hearings on ADHD drugs.
- References
References
1
Food and Drug Administration. Drug Safety and Risk Management Advisory Committee Meeting, February 9 and 10, 2006: table of contents. (Accessed March 16, 2006, at http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202_00_TOC.htm.)
2
Wilens TE ,Hammerness PG ,Biederman J , et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005;66:253-259
CrossRef | Web of Science | Medline3
Nissen SE, Cardiovascular and Renal Drugs Advisory Committee
CrossRef | Web of Science | Medline4
Kingston RL ,Borron SW . The relative safety of ephedra compared with other herbal products. Ann Intern Med 2003;139:385-385
Web of Science | Medline5
Kernan WN ,Viscoli CM ,Brass LM , et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343:1826-1832
Full Text | Web of Science | Medline
- Citing Articles (85)
Citing Articles
1
Sharlene Kaye, Shane Darke. (2012) The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care?. Addiction 107:3, 467-477
CrossRef2
Carlos Treceño, Luis H. Martín Arias, Maria Sáinz, Inés Salado, Pilar García Ortega, Veronica Velasco, Natalia Jimeno, Antonio Escudero, Alfonso Velasco, Alfonso Carvajal. (2012) Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiology and Drug Safetyn/a-n/a
CrossRef3
Peter Greaves. 2012. Cardiovascular System. , 263-324.
CrossRef4
Bora Pajo, Paul Stuart. (2012) A comparative review of “how to” books for parents of ADHD children and “how to” books for parents of typical children. Children and Youth Services Review
CrossRef5
Eitan Nahshoni, Pavel Golubchik, Jonathan Glazer, Jonathan Sever, Boris Strasberg, Shula Imbar, Gal Shoval, Abraham Weizman, Gil Zalsman. (2011) Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment. European Child & Adolescent Psychiatry
CrossRef6
Tamar Green, Ronnie Weinberger, Adele Diamond, Michael Berant, Leora Hirschfeld, Amos Frisch, Omer Zarchi, Abraham Weizman, Doron Gothelf. (2011) The Effect of Methylphenidate on Prefrontal Cognitive Functioning, Inattention, and Hyperactivity in Velocardiofacial Syndrome. Journal of Child and Adolescent Psychopharmacology111207092641008
CrossRef7
Cooper, William O., Habel, Laurel A., Sox, Colin M., Chan, K. Arnold, Arbogast, Patrick G., Cheetham, T. Craig, Murray, Katherine T., Quinn, Virginia P., Stein, C. Michael, Callahan, S. Todd, Fireman, Bruce H., Fish, Frank A., Kirshner, Howard S., O'Duffy, Anne, Connell, Frederick A., Ray, Wayne A., . (2011) ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults. New England Journal of Medicine 365:20, 1896-1904
Full Text8
Gigi H.H. van de Loo-Neus, Nanda Rommelse, Jan K. Buitelaar. (2011) ¿Suspender o no el tratamiento? ¿Durante cuánto tiempo debe mantenerse el tratamiento farmacológico del trastorno por déficit de atención/hiperactividad?. Psiquiatría Biológica
CrossRef9
Paul G. Hammerness, Craig B. H. Surman, Ashley Chilton. (2011) Adult Attention-Deficit/Hyperactivity Disorder Treatment and Cardiovascular Implications. Current Psychiatry Reports 13:5, 357-363
CrossRef10
Ira Shetty, Eric S. Silver, Allan J. Hordof, Pablo H. Goldberg, Leonardo Liberman. (2011) Ablation of supraventricular tachycardia allows more liberal therapy in some children with attention-deficit-hyperactivity disorder. Pediatrics International 53:5, 715-717
CrossRef11
Timothy E Wilens, Nicholas R Morrison, Jefferson Prince. (2011) An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Review of Neurotherapeutics 11:10, 1443-1465
CrossRef12
Paul G. Hammerness, James M. Perrin, Rachel Shelley-Abrahamson, Timothy E. Wilens. (2011) Cardiovascular Risk of Stimulant Treatment in Pediatric Attention-Deficit/Hyperactivity Disorder: Update and Clinical Recommendations. Journal of the American Academy of Child & Adolescent Psychiatry 50:10, 978-990
CrossRef13
Margot Putukian, Jeffrey B Kreher, David B Coppel, James L Glazer, Douglas B McKeag, Russell D White. (2011) Attention Deficit Hyperactivity Disorder and the Athlete: An American Medical Society for Sports Medicine Position Statement. Clinical Journal of Sport Medicine 21:5, 392-400
CrossRef14
Lucy Barnard-Brak, Yen M. To, Danielle D. Fearon. (2011) Protopathic stimulant use among children with symptoms of ADHD. ADHD Attention Deficit and Hyperactivity Disorders 3:3, 245-251
CrossRef15
Gigi H.H. van de Loo-Neus, Nanda Rommelse, Jan K. Buitelaar. (2011) To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?. European Neuropsychopharmacology 21:8, 584-599
CrossRef16
Ciaran S Clarke, Finian Bannon, Norbertas Skokauskas, Ciaran S Clarke. 2011. EEG neurofeedback for inattention in children with Attention Deficit Hyperactivity Disorder (ADHD). .
CrossRef17
Julio A.S. Koneski, Erasmo B. Casella, Fábio Agertt, Maria Gabriela Ferreira. (2011) Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: A Brazilian sample study and literature review. Epilepsy & Behavior 21:3, 228-232
CrossRef18
Yu-Shu Huang, Ming-Horng Tsai. (2011) Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder. CNS Drugs 25:7, 539-554
CrossRef19
Chuan-Yu Chen, Hsueh-Han Yeh, Kuang-Hung Chen, I-Shou Chang, Erin Chia-Hsuan Wu, Keh-Ming Lin. (2011) Differential Effects of Predictors on Methylphenidate Initiation and Discontinuation Among Young People with Newly Diagnosed Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology 21:3, 265-273
CrossRef20
Vincent M. Figueredo. (2011) Chemical Cardiomyopathies: The Negative Effects of Medications and Nonprescribed Drugs on the Heart. The American Journal of Medicine 124:6, 480-488
CrossRef21
H. Zoëga, K. Furu, M. Halldórsson, P. H. Thomsen, A. Sourander, J. E. Martikainen. (2011) Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatrica Scandinavica 123:5, 360-367
CrossRef22
Angela A. Baker, Michele M. Taylor, Jason R. Richardson. 2011. Genetic and Environmental Factors in Attention-Deficit Hyperactivity Disorder. , 257-274.
CrossRef23
, J. Graham, T. Banaschewski, J. Buitelaar, D. Coghill, M. Danckaerts, R. W. Dittmann, M. Döpfner, R. Hamilton, C. Hollis, M. Holtmann, M. Hulpke-Wette, M. Lecendreux, E. Rosenthal, A. Rothenberger, P. Santosh, J. Sergeant, E. Simonoff, E. Sonuga-Barke, I. C. K. Wong, A. Zuddas, H.-C. Steinhausen, E. Taylor. (2011) European guidelines on managing adverse effects of medication for ADHD. European Child & Adolescent Psychiatry 20:1, 17-37
CrossRef24
Wade W. Benton, Adam W. Brothers, Christa C. Jefferis Kirk, Gretchen A. Linggi Irby, Christopher M. Rubino. 2011. Adverse Drug Reactions and Drug-drug Interactions. , 1569-1589.
CrossRef25
J. González Fernández, V. García Morales, J.M. Trejo Gabriel y Galán. (2010) Hemorragia de núcleo caudado por anestesia dental. Neurología 25:9, 586-588
CrossRef26
Gary Stiefel, Frank M.C. Besag. (2010) Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder. Drug Safety 33:10, 821-842
CrossRef27
Sean Hennessy, Hedi Schelleman, Gregory W. Daniel, Warren B. Bilker, Stephen E. Kimmel, James Guevara, Mark J. Cziraky, Brian L. Strom. (2010) Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study. Pharmacoepidemiology and Drug Safety 19:9, 934-941
CrossRef28
Todd E. Elder. (2010) The importance of relative standards in ADHD diagnoses: Evidence based on exact birth dates
. Journal of Health Economics 29:5, 641-656
CrossRef29
William N. Evans, Melinda S. Morrill, Stephen T. Parente. (2010) Measuring inappropriate medical diagnosis and treatment in survey data: The case of ADHD among school-age children
CrossRef30
Mehmet Goksin Karaman, Figen Atalay, Ali Evren Tufan, Ayten Erdogan. (2010) Pulmonary Aterial Hypertension in an Adolescent Treated with Methylphenidate. Journal of Child and Adolescent Psychopharmacology 20:3, 229-231
CrossRef31
Rex Watson, Ryan Woodman, Warren Lockette. (2010) Ephedra alkaloids inhibit platelet aggregation. Blood Coagulation & Fibrinolysis 21:3, 266-271
CrossRef32
Jan Buitelaar, Rossella Medori. (2010) Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. European Child & Adolescent Psychiatry 19:4, 325-340
CrossRef33
J. González Fernández, V. García Morales, J.M. Trejo Gabriel y Galán. (2010) Caudal nucleus haemorrhage due to dental anaesthesia. Neurología (English Edition) 25:9, 586-588
CrossRef34
Eitan Nahshoni, Samuel Sclarovsky, Sara Spitzer, Gil Zalsman, Boris Strasberg, Abraham Weizman. (2009) Early Repolarization in Young Children with Attention-Deficit/Hyperactivity Disorder Versus Normal Controls: A Retrospective Preliminary Chart Review Study. Journal of Child and Adolescent Psychopharmacology 19:6, 731-735
CrossRef35
Frank M.C. Besag. (2009) Attention-Deficit Hyperactivity Disorder (ADHD) Treatment and Sudden Death. Drug Safety 32:11, 1097-1100
CrossRef36
Suzanne McCarthy, Noel Cranswick, Laura Potts, Eric Taylor, Ian C.K. Wong. (2009) Mortality Associated with Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment. Drug Safety 32:11, 1089-1096
CrossRef37
Maria T. Acosta, Mauricio Arcos-Burgos, Maximilian Muenke. 2009. Attention-Deficit/Hyperactivity Disorder. .
CrossRef38
Craig Surman, Paul Hammerness, Katherine Miller. (2009) A 2009 update on adult ADHD. Current Attention Disorders Reports 1:3, 131-136
CrossRef39
Paul Hammerness, Timothy Wilens, Eric Mick, Thomas Spencer, Robert Doyle, Michelle McCreary, Judith Becker, Joseph Biederman. (2009) Cardiovascular Effects of Longer-Term, High-Dose OROS Methylphenidate in Adolescents with Attention Deficit Hyperactivity Disorder. The Journal of Pediatrics 155:1, 84-89.e1
CrossRef40
Lucy Barnard-Brak, Yen To. (2009) Examining Parental Nonresponse to Stimulant Treatment Questions According to Ethnicity. Journal of Child and Adolescent Psychopharmacology 19:3, 301-304
CrossRef41
Bradley K.W. Ng. (2009) Methylphenidate and Psychotic Depression. Clinical Neuropharmacology 32:3, 177
CrossRef42
Jennifer L. Pilgrim, Dimitri Gerostamoulos, Olaf H. Drummer, Marc Bollmann. (2009) Involvement of Amphetamines in Sudden and Unexpected Death. Journal of Forensic Sciences 54:2, 478-485
CrossRef43
Eitan Auriel, Jeffrey M. Hausdorff, Nir Giladi. (2009) Methylphenidate for the Treatment of Parkinson Disease and Other Neurological Disorders. Clinical Neuropharmacology 32:2, 75-81
CrossRef44
Sina Dadfarmay, John Dixon. (2009) A Case of Acute Cardiomyopathy and Pericarditis Associated with Methylphenidate. Cardiovascular Toxicology 9:1, 49-52
CrossRef45
Peter A. Shapiro. (2009) Treatment of depression in patients with congestive heart failure. Heart Failure Reviews 14:1, 7-12
CrossRef46
Jadwiga Najib. (2009) The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Clinical Therapeutics 31:1, 142-176
CrossRef47
Joseph Lynch, Christopher Regan, Gary Stump, Pamela Tannenbaum, Joanne Stevens, Ashleigh Bone, David Gilberto, Colena Johnson, Naoko Fujino, Norihiro Takenaga, Shigeru Tokita, Tsuyoshi Nagase, Nagaaki Sato, John Renger. (2009) Hemodynamic and Cardiac Neurotransmitter-releasing Effects in Conscious Dogs of Attention- and Wake-promoting Agents: A Comparison of d-Amphetamine, Atomoxetine, Modafinil, and a Novel Quinazolinone H3 Inverse Agonist. Journal of Cardiovascular Pharmacology 53:1, 52-59
CrossRef48
Antje Neubert, Miriam CJM Sturkenboom, Macey L. Murray, Katia MC Verhamme, Alfredo Nicolosi, Carlo Giaquinto, Adriana Ceci, Ian CK Wong, . (2008) Databases for pediatric medicine research in Europe-assessment and critical appraisal. Pharmacoepidemiology and Drug Safety 17:12, 1155-1167
CrossRef49
Kristine L. Witt, Michael D. Shelby, Nilda Itchon-Ramos, Melissa Faircloth, Grace E. Kissling, Allan K. Chrisman, Hima Ravi, Hemalatha Murli, Donald R. Mattison, Scott H. Kollins. (2008) Methylphenidate and Amphetamine Do Not Induce Cytogenetic Damage in Lymphocytes of Children With ADHD. Journal of the American Academy of Child & Adolescent Psychiatry 47:12, 1375-1383
CrossRef50
Paul Hammerness, Craig Surman, Katherine Miller. (2008) Update on adult attention-deficit/hyperactivity disorder. Current Neurology and Neuroscience Reports 8:6, 484-489
CrossRef51
Michael W Daly, Geoffrey Custer, Peter D McLeay. (2008) Cardiac Arrest with Pulseless Electrical Activity Associated with Methylphenidate in an Adolescent with a Normal Baseline Echocardiogram. Pharmacotherapy 28:11, 1408-1412
CrossRef52
Jeffrey J. Fong, Lynne Sylvia, Robin Ruthazer, Greg Schumaker, Marisol Kcomt, John W. Devlin. (2008) Predictors of mortality in patients with suspected propofol infusion syndrome. Critical Care Medicine 36:8, 2281-2287
CrossRef53
Marc Lerner, Tim Wigal. (2008) Long-Term Safety of Stimulant Medications. Journal of Psychosocial Nursing and Mental Health Services 46:8, 38-48
CrossRef54
Meika Loe, Leigh Cuttino. (2008) Grappling with the Medicated Self: The Case of ADHD College Students. Symbolic Interaction 31:3, 303-323
CrossRef55
Sanjay Mathew, Dennis Charney. (2008) Anxiety and depression: leading edge of therapy. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 75:3, 171-173
CrossRef56
Timothy E. Wilens. (2008) Effects of Methylphenidate on the Catecholaminergic System in Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology 28:Suppl. 2, S46-S53
CrossRef57
Rossella Medori, J. Antoni Ramos-Quiroga, Miguel Casas, J.J.S. Kooij, Asko Niemelä, Götz-Erik Trott, Emma Lee, Jan K. Buitelaar. (2008) A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry 63:10, 981-989
CrossRef58
Benedetto Vitiello. (2008) Understanding the Risk of Using Medications for Attention Deficit Hyperactivity Disorder with Respect to Physical Growth and Cardiovascular Function. Child and Adolescent Psychiatric Clinics of North America 17:2, 459-474
CrossRef59
Elliot V. Hersh, Paul A. Moore. (2008) Adverse drug interactions in dentistry. Periodontology 2000 46:1, 109-142
CrossRef60
Marc Lerner, Tim Wigal. (2008) Long-Term Safety of Stimulant Medications Used to Treat Children with ADHD. Pediatric Annals 37:1, 37-45
CrossRef61
Marc Lerner, Tim Wigal. (2008) Long-Term Safety of Stimulant Medications Used to Treat Children with ADHD. Psychiatric Annals 38:1, 43-51
CrossRef62
Johnny Graham, David Coghill. (2008) Adverse Effects of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder. CNS Drugs 22:3, 213-237
CrossRef63
Mark L. Wolraich. 2008. Attention-Deficit/Hyperactivity Disorder in Adolescence. , 257-263.
CrossRef64
Suyash Prasad, Chris Steer. (2008) Switching from Neurostimulant Therapy to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder. Pediatric Drugs 10:1, 39-47
CrossRef65
Wendy Weber, Sanford Newmark. (2007) Complementary and Alternative Medical Therapies for Attention-Deficit/Hyperactivity Disorder and Autism. Pediatric Clinics of North America 54:6, 983-1006
CrossRef66
Janine Calver, Frank Sanfilippo, David Preen, Max Bulsara. (2007) Prescribed stimulant use by Western Australians with Attention Deficit Hyperactivity Disorder (ADHD): does amount dispensed exceed the expected authorised use?. Australian and New Zealand Journal of Public Health 31:6, 533-539
CrossRef67
Nicholas Carson. (2007) The Last Normal Child: Essays on the Intersection of Kids, Culture, and Psychiatric Drugs. Journal of the American Academy of Child & Adolescent Psychiatry 46:12, 1680-1681
CrossRef68
L. C. Smoot, L. A. Boothby, R. C. Gillett. (2007) Clinical assessment and treatment of ADHD in children. International Journal of Clinical Practice 61:10, 1730-1738
CrossRef69
Francesco Furlanello, Laura Vitali Serdoz, Riccardo Cappato, Luigi De Ambroggi. (2007) Illicit drugs and cardiac arrhythmias in athletes. European Journal of Cardiovascular Prevention & Rehabilitation 14:4, 487-494
CrossRef70
J.M. Fegert, H. Bode, I. Hach, L. Hargarter, W.E. Müller. (2007) Behandlung mit Methylphenidat im Kindesalter. Monatsschrift Kinderheilkunde 155:8, 747-752
CrossRef71
(2007) Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child & Adolescent Psychiatry 46:7, 894-921
CrossRef72
Eitan Nahshoni, Sara Spitzer, Michael Berant, Gal Shoval, Gil Zalsman, Abraham Weizman. (2007) QT Interval and Dispersion in Very Young Children Treated with Antipsychotic Drugs: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology 17:2, 187-194
CrossRef73
Benedetto Vitiello. (2007) Research in child and adolescent psychopharmacology: recent accomplishments and new challenges. Psychopharmacology 191:1, 5-13
CrossRef74
Donald E. Greydanus, Helen D. Pratt, Dilip R. Patel. (2007) Attention Deficit Hyperactivity Disorder Across the Lifespan: The Child, Adolescent, and Adult. Disease-a-Month 53:2, 70-131
CrossRef75
Paul McNally, Fiona McNicholas, Paul Oslizlok. (2007) The QT interval and psychotropic medications in children. European Child & Adolescent Psychiatry 16:1, 33-47
CrossRef76
Katy Orr, David Taylor. (2007) Psychostimulants in the Treatment of Depression. CNS Drugs 21:3, 239-257
CrossRef77
Hima B. Palakurthi, Matthew M. Parvin, Stuart Kaplan. (2007) Neuroleptic Malignant Syndrome From Aripiprazole in an Agitated Pediatric Patient. Clinical Neuropharmacology 30:1, 47-51
CrossRef78
T. Fikret Ilgenli, Ayhan Congologlu, Cengiz Ozturk, Tumer Turkbay, Onur Akpinar, Fethi Kilicaslan. (2007) Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Advances in Therapy 24:1, 182-188
CrossRef79
Peter Baxter. (2006) Normality and abnormality. Developmental Medicine & Child Neurology 48:11, 867-867
CrossRef80
JOSEPH BIEDERMAN, THOMAS J. SPENCER, TIMOTHY E. WILENS, JEFFERSON B. PRINCE, STEPHEN V. FARAONE. (2006) Treatment of ADHD With Stimulant Medications: Response to Nissen Perspective in The New England Journal of Medicine. Journal of the American Academy of Child & Adolescent Psychiatry 45:10, 1147-1150
CrossRef81
Richard I. Shader, Jessica R. Oesterheld. (2006) Facts and Public Policy. Journal of Clinical Psychopharmacology 26:3, 223-224
CrossRef82
(2006) ADHD Drugs and Cardiovascular Risk. New England Journal of Medicine 354:21, 2296-2298
Full Text83
Joyce A. Generali. (2006) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 41:5, 484-486
CrossRef84
Dan Hurley. (2006) INCREASED VIGILANCE URGED ON RISK OF PSYCHOSIS WITH ADHD DRUGS. Neurology Today 6:9, 33
CrossRef85
Dan Hurley. (2006) INCREASED VIGILANCE URGED ON RISK OF PSYCHOSIS WITH ADHD DRUGS. Neurology Today 6:9, 33,35
CrossRef
- Letters
